NPM1 mutations, present in about 30% of AML cases, correlate with HOX gene expression and impact leukemogenesis through pathways like the CEBPα pathway, which activates CTBP transcriptional regulators and affects the expression of HOXA5, HOXB5, and HOXA10 in NPM1-mutant AMLs [83,84,85,86,87]. This evidence concerns the gene HOXA10 and acute myeloid leukemia.